Nektar Therapeutics | NKTR - Cost Of Sales


Nektar Therapeutics reported $4.43M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
ALKERMES USD 120.7M 47.44M Jun/2026
Amgen USD 1.87B 271M Jun/2026
Baxter International USD 1.93B 118M Jun/2026
BioCryst Pharmaceuticals USD 3.84M 5.68M Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Cara Therapeutics USD 0 0 Mar/2025
Cipla INR 29.71B 3.4B Jun/2026
Dr.Reddys Laboratories INR 39.22B 1.52B Jun/2026
Eisai JPY 51.09B 926M Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Exelixis USD 20.66M 704K Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Grifols EUR 1.51B 184.45M Dec/2025
Halozyme Therapeutics USD 108.68M 67K Jun/2026
Incyte USD 104.96M 457K Jun/2026
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
MacroGenics USD 9.53M 585K Mar/2026
Merck USD 3.14B 200M Jun/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
Takeda JPY 517.6B 42.94B Jun/2026
Teva Pharmaceutical Industries USD 1.98B 30M Jun/2026
Xencor USD 61.66M 50.95M Jun/2025